Corporate Information – Alligator Bioscience

2024-12-20

Regulatory

Alligator Bioscience AB announces outcome of exercise of warrants series TO 9

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, J ...

2024-12-13

Regulatory

13 December 2024 is the last day of trading in warrants series TO 9 in Alligator Bioscience AB (“Alligator Bioscience” or the &# ...

2024-12-04

Regulatory

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX), hereby publishes its financial calendar for 2025: Extraordinary General ...

2024-12-04

Lund, Sweden, November 27, 2024 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Company was notified that th ...

2024-12-03

Regulatory

The board of directors of Alligator Bioscience AB (“Alligator”) has on 3 December 2024 resolved to convert 170,681 series C shar ...

2024-12-02

Regulatory

Alligator Bioscience AB (“Alligator” or the “Company”) hereby announces that the exercise price for warrants series ...

2024-12-02

Regulatory

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...

2024-12-02

Regulatory

Sharpening focus on preparing mitazalimab for Phase 3 and continuing partnering discussions Planned reduction of workforce, mainly wit ...

2024-12-022024-12-02

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...